Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 19/20 | 0.75 |
| ▸ | HTR2A | P28223 | 18/20 | 0.75 |
| ▸ | HTR2B | P41595 | 18/20 | 0.75 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1475874 | 0.86 | HTR2C (1.00) | HTR2CHTR2AHTR2BHTR7 | |
| SCHEMBL1476951 | 0.85 | HTR2C (0.73) | HTR2CHTR2AHTR2BHTR7 | |
| SCHEMBL1477357 | 0.84 | HTR2A (0.77) | HTR2CHTR2AHTR2BHTR7 | |
| SCHEMBL1476628 | 0.83 | HTR2A (0.75) | HTR2CHTR2AHTR2BHTR7 | |
| SCHEMBL1475870 | 0.83 | HTR2A (0.75) | HTR2CHTR2AHTR2BHTR7 | |
| SCHEMBL1476517 | 0.83 | HTR2C (0.75) | HTR2CHTR2AHTR2BHTR7 | |
| SCHEMBL1475214 | 0.81 | HTR2A (0.71) | HTR2CHTR2AHTR2BHTR7 | |
| SCHEMBL1476578 | 0.81 | HTR2A (0.71) | HTR2CHTR2AHTR2BHTR7 | |
| SCHEMBL1477232 | 0.81 | HTR2C (0.71) | HTR2CHTR2AHTR2BHTR7 | |
| SCHEMBL1477555 | 0.80 | HTR2C (0.70) | HTR2CHTR2AHTR2BHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007505908-A | — | — | 2007-03-15 | — | — | JP | claimed |
| EP-1668014-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-14 | — | — | EP | claimed |
| US-20050119295-A1 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | claimed |
| WO-2005040169-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-06 | — | — | WO | claimed |
| US-7897771-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-01 | — | — | US | disclosed |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-17 | — | — | US | disclosed |
| US-20090270370-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-29 | — | — | US | disclosed |
| US-7579470-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-25 | — | — | US | disclosed |
| US-7402680-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-07-22 | — | — | US | disclosed |
| US-20080103132-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-01 | — | — | US | disclosed |
| US-20050119295-A1 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119295-A1 | Fused heterocyclic compounds | TPH1, HTR3A, HTR3B | HTR2C 5/4885HTR2A 9/4885HTR2B 13/4885 |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | HTR2C 5/4885HTR2A 9/4885HTR2B 13/4885 |
| US-20090270370-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | HTR2C 5/4885HTR2A 9/4885HTR2B 13/4885 |
| US-20080103132-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | HTR2C 5/4885HTR2A 9/4885HTR2B 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.